Blog Section

Women are Dying Early Because of no Hormone Replacement Therapy? A study from Yale University School of Medicine

Could something good possibly have come from the flawed Women’s Health Initiative study?  When the WHI was halted in July 2002 due to early results showing an increase in stroke and heart disease, the media hype frightened doctors and patients alike.  The result: abrupt discontinuation of Hormone Replacement Therapy, or HRT, all over the country.

Sadly, peri and post menopausal women went right back to their hot flashes, vaginal dryness, mental fog, and other debilitating symptoms.

 Now we have a new problem in medicine:  Estrogen Avoidance.  Since the mass exodus from Estrogen Therapy after 2002 many women are at risk for dying early.  It is apparent now that we need estrogen to keep our hearts, arteries and bones healthy.  The WHI study was flawed.  The wrong hormones were used–they were not bioidentical and led to side effects.

Look at the abstract below.  This data from Yale translates easily to nearly all peri and postmenopausal women, not just those with a history of hysterectomy.

Have a discussion with your doctor right away.  It is “a matter of considerable urgency.”  Protect yourself from an early death.  Bio-identical HRT properly prescribed and followed will improve your health and your wellbeing.

At medAge, we help patients achieve optimal health, including prescribing bioidentical HRT.  Call for a free phone consultation.  We are here to help you.    828-684-1212

To Your Optimal Health!  Dr. Laura

 

Am J Public Health. 2013 Sep;103(9):1583-8. doi: 10.2105/AJPH.2013.301295. Epub 2013 Jul 18.

The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years.

Sarrel PM1, Njike VYVinante VKatz DL.

Author information

  • 1Departments of Obstetrics and Gynecology and Psychiatry, Yale University School of Medicine, New Haven, CT, USA. philip.sarrel@yale.edu

Abstract

OBJECTIVES:

We examined the effect of estrogen avoidance on mortality rates among hysterectomized women aged 50 to 59 years.

METHODS: 

We derived a formula to relate the excess mortality among hysterectomized women aged 50 to 59 years assigned to placebo in the Women’s Health Initiative randomized controlled trial to the entire population of comparable women in the United States, incorporating the decline in estrogen use observed between 2002 and 2011.

RESULTS: 

Over a 10-year span, starting in 2002, a minimum of 18 601 and as many as 91 610 postmenopausal women died prematurely because of the avoidance of estrogen therapy (ET).

CONCLUSIONS: 

ET in younger postmenopausal women is associated with a decisive reduction in all-cause mortality, but estrogen use in this population is low and continuing to fall. Our data indicate an associated annual mortality toll in the thousands of women aged 50 to 59 years. Informed discussion between these women and their health care providers about the effects of ET is a matter of considerable urgency.

__________________________________________________________________________________________

Leave a Reply

Your email address will not be published. Required fields are marked *